本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Compugen醫療

2.87
+0.280010.81%
盤後2.870.00000.00%16:04 EDT
成交量:79.86萬
成交額:225.07萬
市值:2.71億
市盈率:7.69
高:2.91
開:2.60
低:2.59
收:2.59
52周最高:3.24
52周最低:1.30
股本:9,455.41萬
流通股本:9,245.75萬
量比:2.03
換手率:0.86%
股息:- -
股息率:- -
每股收益(TTM):0.3733
每股收益(LYR):0.3783
淨資產收益率:50.64%
總資產收益率:15.46%
市淨率:3.06
市盈率(LYR):7.59

資料載入中...

2026/04/27

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/04/27

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/04/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/04/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/04/13

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/04/02

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/03/26

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/03/02

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/03/04

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/03/05

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/08/23

[修訂]年度報告

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
2023/08/23

SEC問詢函

Form CORRESP - Correspondence
2023/06/23

SEC問詢函

Form CORRESP - Correspondence
2023/04/14

SEC問詢函

Form CORRESP - Correspondence
2023/02/28

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/10

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/03

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/08/04

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/02/28

[修訂]年度報告

20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/28

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]